Medical Developments International (ASX: MVP) reported a strong Q3 FY26, with revenue surging 19% year-on-year to $10.5 million.
The company also achieved positive operating cash flow and announced significant progress on European paediatric label approvals.
Pain Management revenue, primarily from Penthrox, grew to $8.4 million in Q3 FY26, up 47% year-on-year—a key driver for the quarter.
The Australian hospital segment saw a 26% increase year-to-date, while European in-market volume grew by 19% in the first half of the financial year.
The company is actively managing the impact of US tariffs on Respiratory division input costs by using pricing strategies to offset these pressures.
European Paediatric Approvals Advance
Medical Developments International expects to finalise European paediatric label approvals, preparing to support a new label launch for Penthrox.
Penthrox has already secured approval in 12 European markets.
The company anticipates approval in the UK by August 2026.
This regulatory progress builds on the publication of the MAGPIE paediatric study in Injury and the completion of a health economic study in the first half of FY26.
Cash Flow Turns Positive
Q3 FY26 saw $2.5 million cash generated from operating activities, contributing to a positive year-to-date operating cash flow of $2.8 million.
The company maintained a healthy cash position, ending the quarter on 31 March 2026 with $18.7 million in cash.
Payments to suppliers and employees decreased by $0.7 million in Q3, primarily due to lower inventory purchases.
Q3 FY26 Respiratory revenue was $2.2 million, a decline of $1.0 million compared to the prior comparable period.
Medical Developments International anticipates seasonally softer demand in the Respiratory segment for the second half of FY26, which is expected to result in lower earnings compared to the first half.
Softer demand for Respiratory products in the US has been a contributing factor to the segment's performance.
Supply Chain Risks Monitored
The company is monitoring potential supply-chain impacts from the Middle East conflict.
These disruptions could potentially affect shipping lead times, freight costs and polymer-based input costs.
While these impacts are not expected to be material in FY26, the situation remains uncertain.
Looking Ahead
Medical Developments International is showing strong commercial execution with Penthrox, evidenced by revenue growth and positive cash generation.
The advancement of European paediatric label approvals represents a significant catalyst for future expansion.
However, the company does face headwinds from the softer Respiratory segment and ongoing supply chain uncertainties.
